These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10158764)

  • 1. Evaluating the benefits of antenatal screening: an alternative approach.
    Shackley P; Cairns J
    Health Policy; 1996 May; 36(2):103-15. PubMed ID: 10158764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal screening for cystic fibrosis carriers: an economic evaluation.
    Rowley PT; Loader S; Kaplan RM
    Am J Hum Genet; 1998 Oct; 63(4):1160-74. PubMed ID: 9758600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision making with respect to diagnostic testing: a method of valuing the benefits of antenatal screening.
    Cairns J; Shackley P; Hundley V
    Med Decis Making; 1996; 16(2):161-8. PubMed ID: 8778534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay.
    Miedzybrodzka Z; Semper J; Shackley P; Abdalla M; Donaldson C
    J Med Genet; 1995 Apr; 32(4):282-3. PubMed ID: 7643357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of antenatal screening for cystic fibrosis.
    Cuckle HS; Richardson GA; Sheldon TA; Quirke P
    BMJ; 1995 Dec; 311(7018):1460-3; discussion 1463-4. PubMed ID: 8520332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing value for money in medical screening.
    Cairns JA; Shackley P
    J Med Screen; 1994 Jan; 1(1):39-44. PubMed ID: 8790484
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid testing versus karyotyping in Down's syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalities.
    Gekas J; van den Berg DG; Durand A; Vallée M; Wildschut HI; Bujold E; Forest JC; Rousseau F; Reinharz D
    Eur J Hum Genet; 2011 Jan; 19(1):3-9. PubMed ID: 20842178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration.
    Gill M; Murday V; Slack J
    Soc Sci Med; 1987; 24(9):725-31. PubMed ID: 2440113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antenatal screening for cystic fibrosis.
    Cuckle H; Quirke P; Sehmi I; Lewis F; Murray J; Cross D; Cuckle P; Ozols B
    Br J Obstet Gynaecol; 1996 Aug; 103(8):795-9. PubMed ID: 8760710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of antenatal screening for cystic fibrosis. Authors should have used marginal analysis.
    Torgerson DJ
    BMJ; 1996 Apr; 312(7035):909; author reply 910. PubMed ID: 8611895
    [No Abstract]   [Full Text] [Related]  

  • 13. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs, effects, and savings of screening for cystic fibrosis gene carriers.
    Wildhagen MF; Hilderink HB; Verzijl JG; Verheij JB; Kooij L; Tijmstra T; ten Kate LP; Habbema JD
    J Epidemiol Community Health; 1998 Jul; 52(7):459-67. PubMed ID: 9799881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent economic evaluations of antenatal screening: a systematic review and critique.
    Petrou S; Henderson J; Roberts T; Martin MA
    J Med Screen; 2000; 7(2):59-73. PubMed ID: 11002445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is cystic fibrosis carrier screening cost effective?
    Wei S; Quigg MH; Monaghan KG
    Community Genet; 2007; 10(2):103-9. PubMed ID: 17380060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antenatal screening for Down's syndrome.
    Gutteridge W
    BMJ; 1992 Sep; 305(6856):768; author reply 771. PubMed ID: 1422337
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening should be preferred for medical reasons.
    Morris J
    BMJ; 1996 Apr; 312(7035):908-9; author reply 910. PubMed ID: 8611894
    [No Abstract]   [Full Text] [Related]  

  • 19. Maternal serum triple analyte screening in pregnancy.
    Cate S
    Am Fam Physician; 2000 Aug; 62(4):738, 740. PubMed ID: 10969855
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid aneuploidy test for positive Down screening: who is willing to pay for it?
    Lo TK; Leung WC; Lau WL; Lam H; Lai FK; Ng LS; Wong WC; Chan A; Chin RK
    J Matern Fetal Neonatal Med; 2010 Jul; 23(7):747-9. PubMed ID: 19701862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.